Valitor announced that new preclinical data for its investigational anti-VEGF biologic, VLTR-559, will be presented at the Eyecelerator Conference on October 16, 2025. The conference is held in conjunction with the American Academy of Ophthalmology (AAO) Annual Meeting in Orlando, Florida.
The presentation, titled “Preclinical Tolerability and Retinal Distribution Data Further Support a 6-month Dosing Interval to Treat Wet AMD,” will take place during the 1:15 to 2:45 p.m. ET poster session. Wesley Jackson, Ph.D., Valitor’s president and chief scientific officer, will share findings supporting the potential for VLTR-559 to extend dosing intervals to twice yearly in patients with wet age-related macular degeneration (AMD).
VLTR-559 is a long-acting anti-VEGF therapy developed using Valitor’s proprietary Multivalent Polymer (MVP) technology platform. Current anti-VEGF treatments require frequent intravitreal injections, often every 8–12 weeks, placing a significant burden on patients and clinicians. In preclinical studies, VLTR-559 demonstrated safety and efficacy comparable to approved short-acting anti-VEGF therapies, while remaining in ocular tissues, including the retina, up to three to four times longer. These results suggest a potential for substantial improvements in therapeutic durability without loss of potency.
The MVP technology, developed at U.C. Berkeley, allows for the construction of novel macromolecular drug candidates by combining interchangeable biopolymers and bioactive molecules. This approach enables independent control of critical drug properties such as tissue retention, potency, and safety. In research studies, MVP-based compounds have shown up to 10-fold increases in potency and 5-fold increases in tissue retention compared to conventional therapies.
Valitor is currently advancing VLTR-559 through IND-enabling activities as part of its broader goal to develop long-acting therapies that address major unmet needs in ophthalmology.